البلد: إسرائيل
اللغة: الإنجليزية
المصدر: Ministry of Health
SOLIFENACIN SUCCINATE
TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
G04BD08
TABLETS
SOLIFENACIN SUCCINATE 5 MG
PER OS
Required
TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
SOLIFENACIN
SOLIFENACIN
Solifenacin is indicated for symptomatic treatment of urge incontinence and/or urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
2018-06-30
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS )PREPARATIONS( - 1986 The medicine is dispensed with a doctor’s prescription only SOLIFENACIN TEVA ® 5 MG TABLETS COMPOSITION Each tablet contains: Solifenacin succinate 5 mg SOLIFENACIN TEVA ® 10 MG TABLETS COMPOSITION Each tablet contains: Solifenacin succinate 10 mg Inactive and allergenic ingredients in the preparation - see section 2 “Important information about some of the ingredients of the medicine” and section 6 - “Further Information”. READ THE LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE MEDICINE. This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor or pharmacist. THIS MEDICINE HAS BEEN PRESCRIBED FOR THE TREATMENT OF YOUR AILMENT. DO NOT PASS IT ON TO OTHERS. IT MAY HARM THEM EVEN IF IT SEEMS TO YOU THAT THEIR AILMENT/MEDICAL CONDITION IS SIMILAR. Do not use the medicine in children and adolescents under the age of 18. 1. WHAT IS THE MEDICINE INTENDED FOR? The medicine is intended for the treatment of urinary incontinence and/or conditions of increased urinary frequency and urgency in patients with an overactive bladder. THERAPEUTIC GROUP: Anticholinergics 2. BEFORE USING THE MEDICINE DO NOT USE THE MEDICINE: • If you are sensitive )allergic( to solifenacin or to any of the additional ingredients contained in the medicine. • In case of urinary retention, severe disorders of the digestive system )toxic megacolon(, myasthenia gravis )extreme muscle weakness(, intraocular pressure, accompanied by decreased vision )glaucoma(. • In patients undergoing kidney dialysis and in patients with severe liver insufficiency. • In patients with severe kidney disease or with moderate liver disease, who are being concomitantly treated with another medicine that reduces the clearance of solifenacin from the body, such as ketoconazole. SPECIAL WARNINGS REGARDING USE OF THE MEDICINE BEFORE BEGINNING TREATMENT WITH SOLIFENACIN TEVA, TELL THE DOCTOR IF: You have a pro اقرأ الوثيقة كاملة